Table 2.
The association of CXCL13 and CCL3 with unfavorable parameters
| CXCL13 | GPS | ||||||
|---|---|---|---|---|---|---|---|
| Characteristics | Low | High | P | 0/1 | 2 | P | |
| Age (years) | ≤60 | 32 | 24 | 48 | 8 | ||
| >60 | 3 | 10 | 0.034 | 6 | 7 | 0.005 | |
| Ann Arbor stage | I/II | 30 | 10 | 37 | 3 | ||
| III/IV | 5 | 24 | <0.001 | 17 | 12 | 0.001 | |
| Serum LDH | Normal | 22 | 8 | 28 | 2 | ||
| Increased | 13 | 26 | 0.001 | 26 | 13 | 0.009 | |
| B symptoms | Absence | 25 | 14 | 35 | 4 | ||
| Presence | 10 | 20 | 0.015 | 19 | 11 | 0.017 | |
| LN involvement | Absence | 25 | 15 | 36 | 4 | ||
| Presence | 10 | 19 | 0.029 | 18 | 11 | 0.008 | |
| Primary site | Nasal | 29 | 12 | 38 | 3 | ||
| Extranasal | 6 | 22 | <0.001 | 16 | 12 | 0.001 | |
| Bone marrow invasion | No | 33 | 23 | 49 | 7 | ||
| Yes | 2 | 11 | 0.006 | 5 | 8 | 0.001 | |
| Extranodal involvement | 0/1 | 29 | 14 | 38 | 5 | ||
| ≥2 | 6 | 20 | <0.001 | 16 | 10 | 0.015 | |
| EBV DNA | Non-detectable | 29 | 13 | 38 | 4 | ||
| Detectable | 6 | 21 | <0.001 | 16 | 11 | 0.006 | |
| IPI | L/LI | 30 | 14 | 42 | 2 | ||
| HI/H | 5 | 20 | <0.001 | 12 | 13 | <0.001 | |
| NKPI | Group I/II | 22 | 4 | 24 | 2 | ||
| Group III/IV | 13 | 30 | <0.001 | 30 | 13 | 0.036 |
Abbreviations: LDH lactate dehydrogenase, LN lymph node, EBV Epstein-Barr virus, IPI International Prognostic Index, NKPI NK/T-cell Lymphoma Prognostic Index, GPS Glasgow Prognostic Score.